Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc to develop a therapy for treating pancreatic cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone415-482-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.19 billion
Profitability
Miscellaneous
Employees618
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions
What is Nektar Therapeutics' stock symbol?
Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
How were Nektar Therapeutics' earnings last quarter?
Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Thursday, February, 28th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.70) by $0.13. The biopharmaceutical company earned $39.83 million during the quarter, compared to analyst estimates of $25.97 million. Nektar Therapeutics had a return on equity of 50.22% and a net margin of 57.09%. During the same quarter in the previous year, the business earned ($0.21) earnings per share. View Nektar Therapeutics' Earnings History.
When is Nektar Therapeutics' next earnings date?
What price target have analysts set for NKTR?
11 equities research analysts have issued 1-year price objectives for Nektar Therapeutics' stock. Their predictions range from $38.00 to $100.00. On average, they anticipate Nektar Therapeutics' stock price to reach $72.60 in the next year. This suggests a possible upside of 134.2% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.
What is the consensus analysts' recommendation for Nektar Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nektar Therapeutics.
What are Wall Street analysts saying about Nektar Therapeutics stock?
Here are some recent quotes from research analysts about Nektar Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our 12-month, $47 price target on shares of Nektar is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.24, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2023. Cancer together represent about 71% of our target. In RCC, we assume commercial adoption in patients with PD-L1 expression at <1% (about 67% of the total clear cell RCC opportunity)."" (3/4/2019)
- 2. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019)
- 3. According to Zacks Investment Research, "Nektar has a promising pipeline with several pipeline and regulatory updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik, Adynovate and Neulasta under the license agreement with AstraZeneca, Shire and Amgen, respectively. Also, its recent co-development deal with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 is encouraging. The deals provide revenues as well as reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company. Shares of the company have outperformed the industry in the past six months." (1/14/2019)
Has Nektar Therapeutics been receiving favorable news coverage?
News stories about NKTR stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nektar Therapeutics earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Are investors shorting Nektar Therapeutics?
Nektar Therapeutics saw a decrease in short interest in the month of March. As of March 29th, there was short interest totalling 18,052,597 shares, a decrease of 8.1% from the March 15th total of 19,648,626 shares. Based on an average daily volume of 1,589,216 shares, the short-interest ratio is presently 11.4 days. Approximately 10.5% of the company's shares are short sold. View Nektar Therapeutics' Current Options Chain.
Who are some of Nektar Therapeutics' key competitors?
Some companies that are related to Nektar Therapeutics include BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Marina Biotech (MRNA), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO) and Beigene (BGNE).
What other stocks do shareholders of Nektar Therapeutics own?
Who are Nektar Therapeutics' key executives?
Nektar Therapeutics' management team includes the folowing people:
- Mr. Howard W. Robin, CEO, Pres & Director (Age 66)
- Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)
- Mr. John Nicholson, Sr. VP & COO (Age 67)
- Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60)
- Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)
Who are Nektar Therapeutics' major shareholders?
Nektar Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.42%), Retirement Systems of Alabama (0.13%), Empire Life Investments Inc. (0.05%), Nisa Investment Advisors LLC (0.03%), State of Alaska Department of Revenue (0.03%) and QUANTRES ASSET MANAGEMENT Ltd (0.01%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.
Which institutional investors are selling Nektar Therapeutics stock?
NKTR stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama and DNB Asset Management AS. Company insiders that have sold Nektar Therapeutics company stock in the last year include Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.
Which institutional investors are buying Nektar Therapeutics stock?
NKTR stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Empire Life Investments Inc., Nisa Investment Advisors LLC, New England Research & Management Inc., Traynor Capital Management Inc., QUANTRES ASSET MANAGEMENT Ltd, Strs Ohio and State of Alaska Department of Revenue. View Insider Buying and Selling for Nektar Therapeutics.
How do I buy shares of Nektar Therapeutics?
Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nektar Therapeutics' stock price today?
One share of NKTR stock can currently be purchased for approximately $31.00.
How big of a company is Nektar Therapeutics?
Nektar Therapeutics has a market capitalization of $5.40 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.
What is Nektar Therapeutics' official website?
How can I contact Nektar Therapeutics?
Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]
MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
